摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2E)-1-phenyl-3-[4-(trifluoromethyl)phenyl]prop-2-en-1-one

中文名称
——
中文别名
——
英文名称
(2E)-1-phenyl-3-[4-(trifluoromethyl)phenyl]prop-2-en-1-one
英文别名
(E)-1-phenyl-3-(4-(trifluoromethyl)phenyl)prop-2-en-1-one;(E)-3-(4-trifluoromethylphenyl)-1-phenylprop-2-en-1-one;(E)-3-(4-(trifluoromethyl)phenyl)-1-phenyl-2-propen-1-one;4-trifluoromethylchalcone;(E)-1-phenyl-3-[4-(trifluoromethyl)phenyl]prop-2-en-1-one
(2E)-1-phenyl-3-[4-(trifluoromethyl)phenyl]prop-2-en-1-one化学式
CAS
——
化学式
C16H11F3O
mdl
——
分子量
276.258
InChiKey
QZMAQARJRMCAPU-DHZHZOJOSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    20
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.06
  • 拓扑面积:
    17.1
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (2E)-1-phenyl-3-[4-(trifluoromethyl)phenyl]prop-2-en-1-one1,10-菲罗啉硼氘化钠 、 cerium(III) chloride heptahydrate 、 sodium t-butanolate 作用下, 以 甲醇甲苯 为溶剂, 反应 27.0h, 生成 benzyl alcohol-d1
    参考文献:
    名称:
    Transition-Metal-Free Self-Hydrogen-Transferring Allylic Isomerization
    摘要:
    Phenanthroline and tert-butoxide have been established as powerful radical initiators in reactions such as the S(RN)1-type coupling reactions due to the cooperation of large heteroarenes and a special feature of tert-butoxide. The first phenanthroline-tert-butoxide-catalyzed transition-metal-free allylic isomerization is described. The resulting ketones are key intermediates for indenes. The control experiments rule out the base-promoted allylic anion pathway. The radical pathway is supported by experimental evidence that includes kinetic study, kinetic isotope effect, isotope-labeling experiments, trapping experiments, and EPR experiments.
    DOI:
    10.1021/acs.orglett.5b03124
  • 作为产物:
    描述:
    1-{1-phenyl-3-[4-(trifluoromethyl)phenyl]prop-2-yn-1-yl}piperidine哌啶 作用下, 以 为溶剂, 以60%的产率得到(2E)-1-phenyl-3-[4-(trifluoromethyl)phenyl]prop-2-en-1-one
    参考文献:
    名称:
    吲哚和Ch的溶剂依赖性铜催化形成的合成和机理研究
    摘要:
    已经发现负载在活性炭上的铜纳米颗粒可以催化吡啶-2-甲醛醛衍生物,仲胺和末端炔烃在二氯甲烷中吲哚嗪的多组分合成。然而,在没有溶剂的情况下,形成杂环查耳酮。我们提供了令人信服的证据,表明这两个过程都是通过醛-胺-炔烃偶联中间体进行的。与其他从醛和炔烃形成查耳酮的众所周知的机理相反,提出了一种新的反应途径,其中涉及炔丙基胺作为不进行重排的中间体。吲哚嗪或查耳酮的形成是由感应效应和溶剂效应驱动的,广泛报道了两者。在两个反应中
    DOI:
    10.1021/acscatal.5b00417
点击查看最新优质反应信息

文献信息

  • Iron-Facilitated Oxidative Radical Decarboxylative Cross-Coupling between α-Oxocarboxylic Acids and Acrylic Acids: An Approach to α,β-Unsaturated Carbonyls
    作者:Qing Jiang、Jing Jia、Bin Xu、An Zhao、Can-Cheng Guo
    DOI:10.1021/acs.joc.5b00267
    日期:2015.4.3
    The first Fe-facilitated decarboxylative cross-coupling reaction between α-oxocarboxylic acids and acrylic acids in aqueous solution has been developed. This transformation is characterized by its wide substrate scope and good functional group compatibility utilizing inexpensive and easily accessible reagents, thus providing an efficient and expeditious approach to an important class of α,β-unsaturated
    已经开发出水溶液中α-氧代羧酸与丙烯酸之间的第一个铁促进的脱羧交叉偶联反应。该转化的特征在于其底物范围宽和使用廉价且易于获得的试剂的良好官能团相容性,从而为生物活性化合物中常见的重要一类α,β-不饱和羰基化合物提供了一种有效而快捷的方法。在随后的官能化反应中也证明了偶联产物的合成潜力。初步的机理研究表明,该过程涉及自由基途径:
  • Borylation and selective reduction of α,β-unsaturated ketones under mild conditions catalyzed by Cu nanoparticles
    作者:Xin-Feng Zhou、Yu-Yang Sun、Ya-Dong Wu、Jian-Jun Dai、Jun Xu、Yu Huang、Hua-Jian Xu
    DOI:10.1016/j.tet.2016.07.079
    日期:2016.9
    An effective strategy for synthesis of Cu nanoparticles is designed, these nanoparticles have high catalytic activity in conjugate addition of B2(pin)2 and α,β-unsaturated ketones. The reaction of protodeboration can proceed with adding NaOtBu. In this way, a new method to reduce the conjugated alkenes of α,β-unsaturated ketones is developed with organoboranes as intermediates. Cu nanocrystals also
    设计了一种有效的合成铜纳米颗粒的策略,这些纳米颗粒在B 2(pin)2和α,β-不饱和酮的共轭添加中具有高催化活性。原脱硼的反应可以通过添加NaO t Bu来进行。以这种方式,开发了一种以有机硼烷为中间体,还原α,β-不饱和酮的共轭烯烃的新方法。Cu纳米晶体在克级反应和循环利用实验中也具有优异的性能。提出了一种可能的机制。
  • Asymmetric Conjugate Addition of Organoboron Reagents to Common Enones Using Copper Catalysts
    作者:Chunlin Wu、Guizhou Yue、Christian Duc-Trieu Nielsen、Kai Xu、Hajime Hirao、Jianrong (Steve) Zhou
    DOI:10.1021/jacs.5b11441
    日期:2016.1.27
    Copper complexes of phosphoramidites efficiently catalyzed asymmetric addition of arylboron reagents to acyclic enones. Importantly, rare 1,4-insertion of arylcopper(I) was identified which led directly to O-bound copper enolates. The new mechanism is fundamentally different from classical oxidative addition/reductive elimination of organocopper(I) on enones.
    亚磷酰胺的铜配合物有效地催化芳基硼试剂向无环烯酮的不对称加成。重要的是,鉴定了稀有的芳基铜(I)的 1,4-插入,这直接导致了与 O 结合的铜烯醇化物。新机制与传统的有机铜(I)在烯酮上的氧化加成/还原消除有着根本的不同。
  • [EN] ALLOSTERIC PROTEIN KINASE MODULATORS<br/>[FR] MODULATEURS DE PROTÉINE KINASE ALLOSTÉRIQUE
    申请人:UNIV SAARLAND
    公开号:WO2010043711A1
    公开(公告)日:2010-04-22
    The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.
    该发明提供特定的小分子化合物,这些化合物能够变构调节AGC蛋白激酶的活性或调节Aurora家族蛋白激酶的蛋白-蛋白相互作用,提供这些化合物的制备方法,包含这些化合物的药物组合物,以及它们用于制备治疗和预防与AGC蛋白激酶或Aurora家族蛋白激酶异常活动相关疾病的药物的应用。
  • ALLOSTERIC PROTEIN KINASE MODULATORS
    申请人:Engel Matthias
    公开号:US20120046307A1
    公开(公告)日:2012-02-23
    The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.
    本发明提供了特定的小分子化合物,它们通过变构调节AGC蛋白激酶的活性或调节Aurora家族蛋白激酶的蛋白质-蛋白质相互作用,其生产方法,包含该化合物的药物组合物,以及它们用于制备治疗和预防与AGC蛋白激酶或Aurora家族蛋白激酶异常活动相关疾病的药物的应用。
查看更多